Wegovy and Zepbound carry FDA approval for chronic weight management in adults with obesity or weight-related health conditions
What is the future outlook for oral GLP-1 medications
Compared with naltrexone-bupropion, semaglutide was associated with lower hazards of anxiety disorders, depression, cognitive deficits, and insomnia in adults with type 2 diabetes
doi: 10.1530/EJE-15-0354 3 FieffeSMorangeIPetrossiansPChansonPRohmerVCortetCet al
According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
Most users may experience nausea or vomiting derived by the GLP-1 activity in area postrema and delayed gastric emptying generated by the molecule (154157)
